Mouse LILRB4/CD85k/ILT3 Protein
Catalog No: LILRB4-MP001
- Species
- Mouse
- Expression System
- HEK293
- Tag
- His
Product overview
Recombinant Mouse LILRB4/CD85k/ILT3 Protein is expressed in HEK293 cells with a His tag at the C-terminus. It contains amino acid residues Gly24-Lys238 (UniProt accession: Q64281-1).
Product Details
- Molecular Aliases
- HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K
- Protein Length
- Gly24-Lys238
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 25.1 kDa. Due to glycosylation, the protein migrates to 30-45 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Mouse LILRB4 on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.
The purity of Mouse LILRB4 is greater than 95% as determined by SEC-HPLC.
Background
LILRB4,also known as CD85k and LIR-5, ILT3, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.
References
- Samuel J, Heyu C, Mi D, et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML[J]. Molecular Therapy, 2018:S1525001618303721-. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.